Back to Journals » ClinicoEconomics and Outcomes Research » Volume 5

Analysis of disease patterns and cost of treatments for prevention of deep venous thrombosis after total knee or hip replacement: results from the Practice Analysis of THromboprophylaxis after Orthopaedic Surgery (PATHOS) study

Authors Degli Esposti L, Didoni G, Simon T, Buda S, Sangiorgi D, Esposti E

Received 6 November 2012

Accepted for publication 23 November 2012

Published 28 December 2012 Volume 2013:5 Pages 1—7

DOI https://doi.org/10.2147/CEOR.S39978

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Luca Degli Esposti,1 Guido Didoni,2 Teresa Simon,3 Stefano Buda,1 Diego Sangiorgi,1 Ezio Degli Esposti1

1CliCon Health, Economics and Outcomes Research, Ravenna, Italy; 2BMS Italy, Rome, Italy; 3BMS Global, Princeton, NJ, USA

Introduction: Venous thromboembolism (VTE) is a well-known complication of total hip replacement (THR) and total knee replacement (TKR). Various drugs have been introduced in an attempt to reduce the mortality as well as the short-term and long-term morbidity associated with the development of VTE. The aim of this study was to analyze drug utilization for thromboprophylaxis and the cost of illness in real clinical practice in patients with THR or TKR.
Materials and methods: A multicenter, retrospective, observational cohort study based on local health unit administrative databases was conducted. All patients (≥18 years old) discharged for THR/TKR procedures between January 1, 2007 and December 31, 2008 were included in the study. The date of first hospital discharge was the index date; patients were followed up for a period of 12 months.
Results: A total of 10,389 patients were included: 3516 males (33.8%, 69.4 ± 10.4 years) and 6873 females (66.2%, 71.7 ± 9.0 years), of which 5483 (52.8%) were discharged for THR and 4906 (47.2%) for TKR. First antithrombotic treatments after discharge were enoxaparin (3937, 37.9%), heparin (3752, 36.1%), antiplatelet agents (658, 6.3%), vitamin K antagonists (276, 2.7%), fondaparinux (136, 1.3%), combinations (185, 1.8%), and no therapy (1445, 13.9%). Overall, we observed 2347 (22.6%) treatment changes; median duration of antithrombotic treatment was 23 days (range 11–47) for THR and 22 days (range 11–46) for TKR. During the follow-up period, we observed 129 cases of VTE (120 per 10,000 patients), five post-thrombotic syndrome (4.8 per 10,000 patients), and three heparin-induced thrombocytopenia (2.9 per 10,000 patients). Median cost for both THR and TKR was €9052.00 (range €8063.00–€9084.96), with a median length of stay of 9.0 days (range 6.0–12.0).

Keywords: venous thromboembolism, VTE, total hip replacement, THR, total knee replacement, TKR, real practice, cost of illness, antithrombotic therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Epidemiology, patient profile, and health care resource use for hepatitis C in Italy

Sangiorgi D, Perrone V, Buda S, Boglione L, Cariti G, Lefevre C, Nappi C, Degli Esposti L

ClinicoEconomics and Outcomes Research 2017, 9:609-616

Published Date: 10 October 2017

Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study

Ermini G, Perrone V, Veronesi C, Degli Esposti L, Di Pasquale G

Vascular Health and Risk Management 2017, 13:239-246

Published Date: 5 July 2017

Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy

Degli Esposti L, Veronesi C, Perrone V, Buda S, Santoro A

ClinicoEconomics and Outcomes Research 2017, 9:233-239

Published Date: 27 April 2017

Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study

Perrone V, Sangiorgi D, Buda S, Degli Esposti L

ClinicoEconomics and Outcomes Research 2016, 8:649-655

Published Date: 25 October 2016

Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting

Perrone V, Sangiorgi D, Buda S, Degli Esposti L

ClinicoEconomics and Outcomes Research 2016, 8:591-597

Published Date: 14 October 2016

Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L

Biologics: Targets and Therapy 2015, 9:119-127

Published Date: 6 November 2015

Adherence to statin treatment following a myocardial infarction: an Italian population-based survey

Monaldi B, Bologna G, Costa GG, D'Agostino C, Ferrante F, Filice M, Grion A, Mingarelli A, Paloscia L, Tettamanti R, Veronesi C, Degli Esposti L

ClinicoEconomics and Outcomes Research 2015, 7:273-280

Published Date: 1 June 2015

Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study

Degli Esposti L, Sangiorgi D, Perrone V, Radice S, Clementi E, Perone F, Buda S

ClinicoEconomics and Outcomes Research 2014, 6:401-407

Published Date: 18 September 2014

Drug adherence to olmesartan/amlodipine fixed combination in an Italian clinical practice setting

Degli Esposti L, Saragoni S, Buda S, Degli Esposti E

ClinicoEconomics and Outcomes Research 2014, 6:209-216

Published Date: 22 April 2014

Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases

Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E

ClinicoEconomics and Outcomes Research 2013, 5:193-201

Published Date: 14 May 2013

Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients

Luca Degli Esposti, Stefania Saragoni, Silvia Benemei, et al

ClinicoEconomics and Outcomes Research 2011, 3:47-54

Published Date: 7 March 2011

Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years

Luca Degli Esposti, Stefania Saragoni, Paolo Batacchi, et al

ClinicoEconomics and Outcomes Research 2010, 2:113-120

Published Date: 28 July 2010

Readers of this article also read:

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010